Advertisement

PharmacoEconomics & Outcomes News

, Volume 818, Issue 1, pp 30–30 | Cite as

Talimogene laherparepvec plus ipilimumab not cost effective

Clinical study
  • 10 Downloads

References

  1. 1.
    Almutairi AR, et al. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. JAMA Dermatology : 12 Nov 2018. Available from: URL: http://doi.org/10.1001/jamadermatol.2018.3958.Google Scholar
  2. 2.
    DiMagno SSP, et al. Pricing a Year of Progression-Free Survival: When Is the Cost of Cancer Drugs Unreasonable? JAMA Dermatology : 12 Nov 2018. Available from: URL: http://doi.org/10.1001/jamadermatol.2018.3753.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations